Surging global incidence of solid and hematological malignancies, expanding biopharmaceutical investment in targeted oncology therapies and immunotherapies, and continuous molecular diagnostic innovations in next-generation sequencing (NGS) and liquid biopsy assays are driving rapid growth across the global Companion Diagnostics for Oncology Market. Companion diagnostics (CDx) for oncology...